IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Position Trimmed by Swiss National Bank

Swiss National Bank decreased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 20.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 85,100 shares of the company's stock after selling 21,900 shares during the quarter. Swiss National Bank owned 0.13% of IDEAYA Biosciences worth $3,028,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Federated Hermes Inc. boosted its stake in shares of IDEAYA Biosciences by 14.8% in the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company's stock valued at $138,185,000 after purchasing an additional 500,046 shares during the period. Vanguard Group Inc. boosted its stake in shares of IDEAYA Biosciences by 5.0% in the third quarter. Vanguard Group Inc. now owns 2,971,497 shares of the company's stock valued at $80,171,000 after purchasing an additional 141,844 shares during the period. Boone Capital Management LLC boosted its stake in shares of IDEAYA Biosciences by 15.0% in the third quarter. Boone Capital Management LLC now owns 570,682 shares of the company's stock valued at $15,397,000 after purchasing an additional 74,249 shares during the period. Fisher Asset Management LLC boosted its stake in shares of IDEAYA Biosciences by 1,609.8% in the fourth quarter. Fisher Asset Management LLC now owns 539,025 shares of the company's stock valued at $19,179,000 after purchasing an additional 507,500 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of IDEAYA Biosciences by 199.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 437,356 shares of the company's stock valued at $11,800,000 after purchasing an additional 291,240 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

IDYA stock traded up $0.38 during midday trading on Wednesday, reaching $41.38. 1,284,170 shares of the company were exchanged, compared to its average volume of 822,209. IDEAYA Biosciences, Inc. has a 1-year low of $20.90 and a 1-year high of $47.74. The stock's 50-day simple moving average is $41.82 and its 200 day simple moving average is $39.36. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -20.40 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. The firm's revenue for the quarter was down 100.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.49) EPS. On average, research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on IDYA shares. BTIG Research began coverage on shares of IDEAYA Biosciences in a research note on Friday, March 8th. They issued a "buy" rating and a $55.00 price objective for the company. Citigroup lifted their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, March 21st. Capital One Financial reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. Wedbush reiterated an "outperform" rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an "overweight" rating in a research note on Friday, February 23rd. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $46.80.

Insider Activity

In other news, CEO Yujiro S. Hata sold 56,711 shares of IDEAYA Biosciences stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $41.61, for a total value of $2,359,744.71. Following the transaction, the chief executive officer now directly owns 677,887 shares of the company's stock, valued at approximately $28,206,878.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 34,433 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total value of $1,439,643.73. Following the transaction, the chief executive officer now directly owns 677,887 shares of the company's stock, valued at approximately $28,342,455.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yujiro S. Hata sold 56,711 shares of the business's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at $28,206,878.07. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.